Record: 21

03/10/2023

Company Report

Pages: 6

Systemic Sclerosis Phase 2 Trial Initiation in 2023, Funded Into 2025

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Record: 22

03/10/2023

Daily Note

Pages: 12

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Record: 23

03/06/2023

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Record: 24

03/03/2023

Company Report

Pages: 18

Efzofitimod Has Potential in Fibrotic Lung Diseases - Resume Buy, $9 PT

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Record: 25

03/01/2023

Daily Note

Pages: 6

Efzofitimod Expands Clinical Journey to SSc-ILD; Phase 2 Study to Begin in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Record: 26

02/07/2023

Company Report

Pages: 7

Milestone Payment Triggered as Phase 3 EFZO-FIT Begins Dosing In Japan; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Record: 27

12/15/2022

Daily Note

Pages: 5

Long-Term Pipeline View; New Target Identified as EFZO-FIT Phase 3 Remains Focus; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Record: 28

11/11/2022

Company Report

Pages: 7

3Q22 Results; All Focus on EFZO-FIT Enrollment as Geographies Expanding

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Record: 29

10/11/2022

Daily Note

Pages: 5

tRNA Synthetase-Based Pipeline Looks to Grow With New R&D Collaboration

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Record: 30

09/06/2022

Daily Note

Pages: 10

Novel NRP2 Antibody Provides Partial Window Into Commercial Profile With Improved Patient Selection Stratification

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Record: 31

08/16/2022

Company Report

Pages: 9

2Q22 Results; Pivotal EFZO-FIT Up and Running; FPI Shortly; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Record: 32

07/21/2022

Company Report

Pages: 9

Specialists Appear Quite Excited With Steroid Sparing and Efzo''s Differentiation, and So Do We; Target Increased to $35

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Record: 33

06/10/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Record: 34

06/10/2022

Company Report

Pages: 4

Transferring Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Record: 35

05/27/2022

Industry Report

Pages: 7

1Q2022 - Cash Balance and Upcoming Catalysts For Our Biotech Coverage Universe

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Record: 36

05/18/2022

Company Report

Pages: 8

Visit to Peninsula''s Lance Project in Wyoming as Site Remains Poised for Ramp-Up in Production; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Record: 37

05/17/2022

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Record: 38

05/17/2022

Company Report

Pages: 5

Design of Phase 3 Sarcoidosis Study Increases Odds of Success

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 5.00

Record: 39

05/16/2022

Daily Note

Pages: 5

EFZO-FIT Looks to Bring Efzofitimod Across the Finish Line; Trial to Begin in 3Q22.

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Record: 40

05/11/2022

Company Report

Pages: 5

1Q22 Update - Study Initiations in Sarcoidosis & Solid Tumors On Track

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 5.00